Alimera Announces Approval and Pricing Granted for ILUVIEN® for Uveitis in Italy ATLANTA, July 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...